Bullous Myringitis: A Comprehensive Overview

Introduction

Bullous myringitis is a distinctive and often dramatic otological condition characterised by the formation of painful, fluid-filled blisters (bullae) on the tympanic membrane (eardrum). Although first described over a century ago, its clinical relevance remains significant due to its acute presentation, potential complications, and implications for patient care.

Historically, bullous myringitis was once thought to be a rare subtype of otitis media. However, advances in diagnostic techniques and a deeper understanding of its pathogenesis have highlighted its unique clinical and pathological features.

Epidemiology

Prevalence

Bullous myringitis accounts for a small but clinically significant proportion of ear infections. Its exact incidence is difficult to ascertain due to variations in diagnostic criteria and underreporting. Studies suggest that it represents approximately 5-10% of all cases of acute otitis media seen in outpatient clinics. The prevalence may be higher in certain populations, particularly where upper respiratory tract infections are common.

Age Groups Affected

The condition can affect individuals of all ages but is most frequently observed in children and young adults. Children aged between 2 and 10 years are particularly susceptible, likely due to their increased risk of respiratory tract infections and anatomical factors such as a shorter, more horizontal Eustachian tube. Nonetheless, adults and elderly individuals are not immune, especially those with predisposing factors.

Geographic Distribution

Bullous myringitis occurs worldwide, with no specific predilection for any geographic region. However, its incidence may be influenced by seasonal factors, with peaks during colder months corresponding to higher rates of viral respiratory infections. Socioeconomic status, access to healthcare, and vaccination coverage also play roles in its distribution.

Etiology and Pathophysiology

Causes

Bullous myringitis is primarily an infectious process, most commonly associated with viral or bacterial pathogens. Historically, Mycoplasma pneumoniae was considered the classic causative agent, but current evidence indicates a broader spectrum:

• Bacterial Pathogens: Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pyogenes are frequently implicated. Mycoplasma pneumoniae remains a notable cause, particularly in children and adolescents.
• Viral Pathogens: Respiratory syncytial virus (RSV), influenza viruses, adenoviruses, and enteroviruses have also been associated with bullous myringitis.

Risk Factors

Several factors can predispose individuals to develop bullous myringitis:

• Recent or concurrent upper respiratory tract infection
• History of recurrent otitis media
• Immunosuppression or chronic illnesses (e.g., diabetes, HIV)
• Exposure to tobacco smoke or air pollution
• Inadequate immunisation status, particularly against influenza and pneumococcus
• Age (children and young adults at greater risk)

Pathogenesis

The pathophysiology of bullous myringitis involves the acute inflammation of the tympanic membrane, leading to the formation of serous or haemorrhagic bullae. The precise mechanism is not fully understood but is believed to involve:

• Direct infection of the mucosal lining of the tympanic membrane by pathogens
• Inflammatory response with increased vascular permeability, allowing fluid accumulation between the epithelial and connective tissue layers of the membrane
• Possible extension of infection from the middle ear cavity, especially in cases associated with acute otitis media

The resulting bullae can be serous (clear fluid) or haemorrhagic (blood-filled), depending on the severity of vascular involvement.

Clinical Presentation

Signs and Symptoms

The hallmark of bullous myringitis is the sudden onset of severe ear pain (otalgia), often disproportionate to other findings. Key features include:

• Otalgia: Intense, sharp, or throbbing ear pain, sometimes radiating to the jaw or neck
• Hearing Loss: Conductive hearing loss of varying severity, usually transient
• Aural Fullness: Sensation of blockage or pressure in the affected ear
• Otorrhoea: Discharge may occur if bullae rupture, releasing serous or blood-tinged fluid
• Tinnitus: Ringing or buzzing in the ear is less common but may be reported
• Systemic Symptoms: Fever, malaise, and irritability, especially in children

Physical Findings

Otoscopy reveals characteristic findings:

• Multiple, tense, translucent or haemorrhagic bullae on the tympanic membrane
• Erythema and oedema of the tympanic membrane
• Possible coexisting signs of acute otitis media (bulging, loss of landmarks, effusion)
• Rarely, bullae may extend to the external auditory canal

Diagnosis

Clinical Examination

Diagnosis is primarily clinical, based on history and otoscopic findings. The presence of bullae on the tympanic membrane in a patient with acute ear pain is highly suggestive.

Differential Diagnosis

Several other conditions can mimic bullous myringitis and should be considered:

• Acute otitis media without bullae
• Herpes zoster oticus (Ramsay Hunt syndrome)
• Otitis externa with canal bullae
• Tympanic membrane trauma or haemorrhage
• Cholesteatoma (rarely presents acutely with bullae)

Investigations

• Otoscopy: Essential for visualising bullae and assessing tympanic membrane mobility and integrity.
• Tympanometry: May show reduced compliance if effusion is present.
• Audiometry: Pure-tone audiometry can document conductive hearing loss and monitor recovery.
• Laboratory Tests: Generally not required in uncomplicated cases. If systemic infection is suspected, complete blood counts, inflammatory markers, or cultures may be indicated.
• Microbiological Swabs: If otorrhoea is present, a swab for bacterial culture may help guide antibiotic therapy.

Treatment

Medical Management

The management of bullous myringitis involves both symptomatic relief and eradication of the underlying infection. Key principles include:

• Pain Control: Analgesics such as paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) are first-line. Severe pain may require short-term use of opioid analgesics.
• Antibiotics: Empirical antibiotic therapy is recommended, especially in children, immunocompromised patients, or when bacterial infection is likely. Amoxicillin or amoxicillin-clavulanate is commonly used; macrolides (e.g., azithromycin) may be considered for suspected Mycoplasma infection or in penicillin-allergic patients. Therapy duration is typically 7-10 days.
• Topical Treatments: Topical antibiotics are not generally indicated unless otorrhoea is present and the external canal is involved.
• Supportive Care: Adequate hydration, rest, and antipyretics for fever. Decongestants and antihistamines are not routinely recommended.

Surgical Interventions

Surgical management is rarely required. In cases of severe pain or persistent bullae, gentle puncture of the bullae under sterile conditions may be performed by an otolaryngologist to relieve discomfort and facilitate drainage. However, this should be undertaken with caution to avoid secondary infection or tympanic membrane damage.

If tympanic membrane perforation occurs with persistent otorrhoea, further management may include regular aural toilet, topical antibiotics, and follow-up to ensure healing.

Complications

While most cases resolve without sequelae, bullous myringitis can be associated with several potential complications:

• Hearing Loss: Usually transient and conductive, but rarely may become persistent if there is tympanic membrane scarring or ossicular involvement.
• Tympanic Membrane Perforation: Rupture of bullae may cause small perforations, which typically heal spontaneously but can occasionally persist.
• Secondary Bacterial Infection: Especially if bullae rupture and the integrity of the tympanic membrane is compromised.
• Chronic Otitis Media: Rarely, unresolved infection can progress to chronic suppurative otitis media.
• Mastoiditis: Extension of infection to the mastoid air cells is a rare but serious complication.

Prognosis

The overall prognosis for bullous myringitis is excellent. With appropriate treatment, most patients experience rapid symptom resolution within 3-7 days, and full recovery is expected in the majority of cases. Hearing typically returns to baseline within a few weeks. Persistent hearing loss, chronic perforation, or other long-term sequelae are rare, especially with timely intervention.

Recurrences are uncommon but may occur in individuals with underlying risk factors such as recurrent respiratory infections or immunosuppression.

Prevention

Vaccination

Preventive strategies focus on reducing the incidence of upper respiratory tract infections and otitis media. Vaccination plays a crucial role:

• Pneumococcal Vaccines: Reduce the risk of infections caused by Streptococcus pneumoniae.
• Influenza Vaccines: Annual vaccination limits the incidence of influenza-associated ear infections.
• Haemophilus influenzae type b (Hib) Vaccine: Particularly important in children.

Hygiene and Public Health Measures

• Promoting good hand hygiene and respiratory etiquette to limit the spread of respiratory pathogens
• Reducing exposure to tobacco smoke and other environmental pollutants
• Timely treatment of respiratory tract infections to prevent secondary ear involvement
• Ensuring up-to-date immunisation status, especially in children and high-risk groups

Recent Advances and Research

Recent research in bullous myringitis has focused on better understanding its microbiological profile, refining diagnostic criteria, and exploring novel therapeutic strategies.

• Molecular Diagnostics: Polymerase chain reaction (PCR) techniques have improved the identification of causative pathogens, including atypical bacteria and viruses, allowing for more targeted therapy.
• Antibiotic Stewardship: Ongoing studies aim to optimise antibiotic use, balancing effective treatment with the need to reduce antimicrobial resistance.
• Vaccination Impact: Recent epidemiological studies demonstrate significant reductions in otitis media and related complications in populations with high vaccination coverage.
• Pain Management Research: Investigations into non-opioid analgesics and topical therapies continue to seek improved patient comfort with fewer side effects.

Emerging data also suggest that host immune responses, genetic predispositions, and environmental factors may influence susceptibility and disease severity. Future research may yield new preventive and therapeutic interventions tailored to individual patient profiles.

Nursing Care of Patients with Bullous Myringitis

Nursing Interventions

• Pain Management:
• Administer prescribed analgesics such as paracetamol or ibuprofen as per doctor’s order.
• Apply warm compresses over the affected ear to relieve pain, if recommended.

Medication Administration:

• Administer antibiotics if prescribed, as bullous myringitis can be caused by bacterial infection.
• Instil ear drops as ordered, ensuring correct technique and aseptic precautions.

Prevention of Infection Spread:

• Maintain strict hand hygiene before and after patient contact.
• Educate the patient and family about not inserting objects into the ear and avoiding water entry into the ear canal during bathing.

Monitoring for Complications:

• Observe for signs of tympanic membrane rupture, increased pain, persistent fever, or purulent discharge.
• Report any abnormal findings to the physician promptly.

Supportive Care:

• Provide a quiet environment to minimise discomfort from noise sensitivity.
• Encourage adequate rest and hydration.

Patient and Family Education

• Explain the nature and course of bullous myringitis, including expected symptoms and duration.
• Instruct on the importance of completing the full course of prescribed antibiotics.
• Advise on ear care: keeping the ear dry, avoiding cotton buds and other foreign objects, and recognising warning signs that require medical attention (e.g., persistent pain, discharge, or hearing loss).
• Inform about follow-up appointments for re-evaluation of ear condition.

Discharge Planning and Follow-Up

• Ensure the patient or caregiver understands the medication schedule and ear care instructions.
• Provide written instructions for home care and emergency contact information.
• Arrange for follow-up visits as recommended by the healthcare provider.

REFERENCES

1. Devaraja K. Myringitis: An update. https://pubmed.ncbi.nlm.nih.gov/30936899/. J Otol. 2019 Mar;14(1):26-29.
2. Earwood J, Rogers T, Rathjen N. Ear Pain: Diagnosing Common and Uncommon Causes. https://pubmed.ncbi.nlm.nih.gov/29365233/. Am Fam Physician. 2018: 97(1). 20-27.
3. Merck Manuals, Professional Version. Myringitis. https://www.merckmanuals.com/professional/ear,-nose,-and-throat-disorders/middle-ear-and-tympanic-membrane-disorders/myringitis.
4. Voruz F, Guinand N. La myringite bulleuse démystifiée [Bullous myringitis demystified]. Rev Med Suisse. 2023 Oct 4;19(844):1774-1779. French. doi: 10.53738/REVMED.2023.19.844.1774. PMID: 37791690.
5. PediatricEducation.org. How Common Is Bullous Myringitis. https://pediatriceducation.org/2013/04/08/how-common-is-bullous-myringitis/?
6. Kasinathan S, Kondamudi NP. Bullous Myringitis. [Updated 2023 Aug 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK553029/

Stories are the threads that bind us; through them, we understand each other, grow, and heal.

JOHN NOORD

Connect with “Nurses Lab Editorial Team”

I hope you found this information helpful. Do you have any questions or comments? Kindly write in comments section. Subscribe the Blog with your email so you can stay updated on upcoming events and the latest articles.